Studies on two new vitamin D analogs, EB 1089 and KH 1060: Effects on bone resorption and osteoclast recruitment in vitro

Abstract

We have investigated the effects on bone resorption of two new potent antiproliferative vitamin D3 analogs, EB 1089 and KH 1060, by studying recruitment of osteoclasts in murine bone marrow cultures and 45Ca release from prelabeled neonatal mouse calvarial bones. Binding studies to vitamin D receptor protein, from human osteosarcoma MG-63 cells, demonstrated k d values of 8.5 × 10 −11 for 1α,25(OH) 2D 3, 6.5 × 10 −11 for KH 1060, and 2.7 × 10 −10 for EB 1089. 1α,25(OH) 2D 3 and EB 1089 were equipotent stimulators of osteoclast recruitment in murine bone marrow cultures, with EC 50 at 10 −10 mol/L, whereas KH 1060 was about tenfold more potent with an EC 50 at 10 −11 mol/L. In serum-free media, 1α,25(OH) 2D 3 enhanced 45Ca release from neonatal mouse calvarial bones with EC 50 at 10 −11 mol/L, but in the presence of 10% fetal calf serum (FCS) the stimulatory effect was significantly diminished, with a threshold value at 10 −10 mol/L. EB 1089 stimulated bone resorption with an estimated EC 50 at 3 × 10 −11 mol/L, whereas KH 1060 was about tenfold more potent than 1α,25(OH) 2D 3, and stimulated bone resorption with an EC 50 at 10 −12 mol/L. The effects of EB 1089 and KH 1060 on 45Ca release were not significantly affected by the addition of 10% FCS. Addition of vitamin D binding protein to serum-free incubations of neonatal mouse calvarial bones significantly inhibited the bone resorbing effect of 1α,25(OH) 2D 3, but did not affect EB 1089 and KH 1060 induced 45Ca release. These data show that the k d values for the binding to Vitamin D receptors are similar to the EC 50 values for stimulation of bone resorption and osteoclast differentiation, in vitro, for 1α,25(OH) 2D 3, EB 1089, and KH 1060. The discrepancy in the effect of FCS on 45Ca release between 1α,25(OH) 2D 3, and the new analogs suggests that EB 1089 and KH 1060 do not bind to vitamin D binding protein, indicating that pharmacokinetic differences may partially explain their less calcemic effects in vivo.